Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Asetek’s Second Quarter 2024 Results on Tuesday, 13 August

Asetek will release its financial results for the second quarter and first half year of 2024 on Tuesday, 13 August around 11:00 CEST. CEO André Sloth Eriksen and CFO Peter Dam Madsen will present and comment on the Company's results at 14:30 CEST and invite investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast or conference call. Webcast - audio and slide presentation: Please join the results webcast via the following link: https://events.q4inc.com/attendee/357370961

Aixia secures an order regarding a communication solution for datacenter architecture, value SEK 2.1 million.

Mölndal                                                                                      2024-08-06 Aixia secures an order regarding a communication solution for datacenter architecture with a European energy company and its Swedish division. The solution is based on Arista and ensures that the company can continue to grow and develop around AI in a safe way. The value of the order amounts to SEK 2.1 million We thank you for the trust and note that the energy sector has enormous potential regarding both safety and efficiency with the help of AI, says Mattias Bergkvist, CEO at

Faron Appoints Dr. Petri Bono as new CMO

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Faron Appoints Dr. Petri Bono as new CMO   Company announcement, 6 August 2024 at 8:30 a.m. BST / 10:30 a.m. EEST   TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in treatment resistant hematological malignancies and solid tumors, is pleased to announce the appointment of Dr. Petri Bono (M.D., Ph.D.) as the new Chief Medical

New Bothnian Coastal Route - between sky and sea

The Bothnian Coastal Route stretches between sea and sky along the northernmost coasts of the Baltic Sea. Two countries border the Bay of Bothnia high up in the north, which merge on a road trip into this adventurous, arctic destination. Photo: Bothnian Coastal Route (Download)  At the heart of the Nordic coastal region lies the Bay of Bothnia, a wide, shallow and northernmost inlet of the Baltic Sea. The name is related to the Swedish name for this part of the Baltic Sea, Bottenhavet (Bottom Sea). Here, at the point where the sea

Kid ASA - Invitation to presentation of Second quarter 2024 results

Lier, 6 August 2024: Kid ASA will release its second quarter 2024 results on Thursday 22 August 2024. The quarterly report and presentation material will be available on http://investor.kid.no and http://newsweb.no from 07:30 CEST. The results will be presented at 08:30 CEST by CEO Anders Fjeld and CFO Mads Kigen as a live webcast hosted by Arctic Securities. The presentation will be broadcasted as a live webcast in English and a recorded version will be made available at http://investor.kid.no. Please sign up for the webcast with the following link: https://forms.office.com/e/

Publication of Anora’s Half-year Report for January–June 2024 on 20 August 2024 and invitation to results presentation

Anora Group Plc   Press release   6 August 2024 at 10:00 a.m. EEST Publication of Anora’s Half-year Report for January–June 2024 on 20 August 2024 and invitation to results presentation Anora will publish its Half-year Report for January–June 2024 on Tuesday 20 August 2024 at around 8:30 am EEST. CEO Jacek Pastuszka and CFO Stein Eriksen will present the report on the same day at 11:00 am EEST. The presentation will be held as a Microsoft Teams Meeting and we recommend joining the event through the online option: Join meeting here 

Cinven to become lead investor in Vitamin Well

International private equity firm, Cinven, today announces that it has reached an agreement to become the lead investor in Vitamin Well (‘the Company’), the Swedish provider of protein bars and sport and health beverages. Bridgepoint, the current majority investor, will retain a significant minority stake in Vitamin Well going forward. Financial details of the transaction are not disclosed. Established in 2008 and headquartered in Stockholm, Vitamin Well is a fast-growing functional food and beverage business, offering premium products for health-conscious and active consumers. Today,

Chassis upgrade for campers with shock absorbers from BILSTEIN Unlimited freedom thanks to a perfect driving experience

Essen, 06 August 2024 – Whether it's an adventurous journey through the unknown or the annual trip to your favourite place: if you want to enjoy boundless freedom in your camper thanks to the perfect driving experience, a visit to the BILSTEIN stand at the Düsseldorf Caravan Salon is a must. From 31 August to 8 September, chassis expert BILSTEIN will be exhibiting its BILSTEIN B6 Camper and B6 Camper Advanced shock absorbers, specially developed for camper vans, for the first time at the Caravan Salon in Hall 13, Stand A51. These high-performance shock absorbers have been specially developed

Scandinavian ChemoTech’s Animal Care Announces New Partnership

Scandinavian ChemoTech’s Animal Care proudly begins the third quarter of 2024 by securing a significant new order with The Woodlands Animal Cancer and Referral Center in Houston, Texas, one of the ten most populated cities in the USA. This order amounts to approximately USD 36,000 and marks another milestone in our commitment to advancing veterinary care.   The Woodlands Animal Cancer and Referral Center, one of the leading veterinary specialty hospitals in the Greater Houston area, has added our innovative vetIQure™ TSE system its state-of-the-art facility. This addition is a

BlueNord: Preliminary Production for July 2024

Oslo, 6 August 2024: BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for July 2024. The Company had a preliminary production in July of net 24.9 mboepd of which 0.6 mboepd is from the Harald field which has had a stable production through the new Tyra facilities since 15 July 2024. The production during the month from the Dan, Gorm and Halfdan hubs remains strong and in line with expectations  The Company reiterates its quarterly production guidance for Q3 2024 of 29.0 – 36.0 mboepd. This information is subject to disclosure

Repurchases of shares during week 31

Between 29 July and 2 August 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 158,008 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 150,000,000 that Attendo announced on 19 July 2024. The repurchase program, which runs between 22 July 2024 and 24 October 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No

Observe Medical ASA: Redelivery of lent shares to person closely associated with primary insider and mandatory notification of trade

Oslo, 6 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 17 July 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS in connection with tranche 2 of the private placement of new shares in the Company (the "Private Placement"). The share capital increase pertaining to tranche 2 of the Private Placement has now been registered, as announced by the Company yesterday, and the shares that were lent by Ingerø Reiten Investment Company AS have been

Oneflow’s monthly ARR update: July 2024

Press release6 August 2024 Oneflow publishes its preliminary monthly ARR. Oneflow had a total ARR (Annual Recurring Revenue) of MSEK 153.3 by the end of July 2024. This is a preliminary number. All financial reports and presentations are available for download on our website here: https://oneflow.com/ir/investors/financial-reports/ For further information, please contact: Anders Hamnes, CEO and FounderMobile: +46 76 788 50 76Email: anders.hamnes@oneflow.com Certified Adviser is FNCA Sweden AB. About Oneflow Oneflow develops a contract automation platform

Lyvia Group acquires Dokeos Limited and enters Belgium

August 6, 2024: Lyvia Group, the European partner for business-critical tech and software solutions, acquires Dokeos Limited, a leading Learning Management System specializing in regulated industries. With this acquisition, Lyvia Group strengthens their offering within SaaS and business-critical software and enters the Belgian market. Dokeos is a leading Learning Management System specializing in regulated industries. Their flagship product xLms is based on their own IP and used by over 2 million users and more than 400 clients. Operating on a pure SaaS model and complemented by

Change in Terveystalo's Executive Team: Chief Medical Officer Petri Bono leaves the company

Terveystalo Plc, stock exchange release 6 August 2024 at 9:00 a.m. EEST   Petri Bono, who has served as Terveystalo's Chief Medical Officer and member of the Executive Team since 2019, has announced that he will leave the company on 14 August 2024 to take up a new position outside the company.   -          Under Petri's leadership, a strong team has been built in the medical management and our quality is among the best in the industry. I warmly thank Petri for his excellent work, for example, in managing the challenging coronavirus years and taking our medical management

Postponement of Tender 1 FY25

    06 August 2024  LSE: PDL     Petra Diamonds Limited (Petra or the Company)   Postponement of Tender 1 FY25   Richard Duffy, Chief Executive Officer of Petra, commented:   “We have taken the proactive decision to defer the upcoming August/September tender from our South African operations, to support steps taken by major producers to restrict supply in this weaker demand period. Our expectation is that supply discipline, together with the expected seasonally stronger demand as we head towards the festive season, will provide some pricing

Transaction in Own Shares

    6 August 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |05/08/2024|+-------------------------------------------------------------

Detection Technology Plc half-yearly report January-June 2024

Detection Technology Plc company announcement 6 August 2024 at 09:00 (EEST) DETECTION TECHNOLOGY PLC HALF-YEARLY REPORT JANUARY-JUNE 2024 Detection Technology Q2 2024: Strong result, record industrial sales April-June 2024 highlights · Net sales increased by 3.5% to EUR 26.1 million (25.2) · Net sales of Industrial Solutions Business Unit (IBU) increased by 42.6% to EUR 5.3 million (3.7) · Net sales of Medical Business Unit (MBU) decreased by -25.3% to EUR 9.3 million (12.4) · Net sales of Security Business Unit (SBU) increased by 26.7% to EUR 11.5 million (9.1) ·

UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors

· Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies · Strengthening of the Board of Directors with late-stage drug development expertise follows read-out of three Phase 2/2b studies with orismilast and prior to initiation of Phase 3 studies with orismilast in atopic dermatitis (AD)   Hellerup, Denmark, August 6, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused

Immunovia announces final terms of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.     LUND (SWEDEN) – On 20 May 2024, the board of directors of Immunovia AB (“Immunovia” or the “Company”) resolved on an issue of units, consisting of shares and warrants, with preferential rights for the Company’s

Conversion of Scandic’s convertible bonds in an aggregated nominal amount of SEK 148.2 million to shares

In 2021 Scandic Hotels Group AB (publ) (“Scandic”) issued convertible bonds in an aggregated nominal amount of SEK 1,800 million. Convertible bonds in an aggregated nominal amount of SEK 148.2 million have been converted to shares. After the conversion, the aggregated nominal amount for the outstanding convertible bonds amounts to SEK 519.5 million.Through the conversion, the total number of shares and votes in Scandic increases with 3,417,730 to in total 207,177,418. Through the conversion, the share capital increases with SEK 854,432.50 to in total SEK 51,794,354.50. For more

47,000 companies have not filed their beneficial owner details – the PRH deregisters companies that have not filed their beneficial owner details by 20 November 2024

The Finnish Patent and Registration Office (PRH), which maintains the Finnish Trade Register, will deregister companies that have not filed their beneficial owner details despite requests to do so. This week, the PRH made an entry in the Finnish Trade Register of limited liability companies and co-operatives that have not filed their beneficial owner details despite the request. These companies will be ordered into liquidation or removed from the Finnish Trade Register if they do not file their notification of beneficial owners by 20 November 2024.Deregistration will take place in December

There are no items matching the current filter
There are no more items matching the current filter
Back to top